By Wendy K. D. Selig, president and CEO of Melanoma Research Alliance
By Robert Weiner and Patricia Berg, PhD
You can’t sequester cancer. You can only hurt the research to treat and prevent the diseases, and stop the treatments themselves.
Large medical centers across the U.S. are investing in a burgeoning area of healthcare for their cancer patients: precision medicine. Substantial investments are being made to not only build new laboratory facilities and purchase research equipment, but also to staff these new facilities.
By Karen Elkins, PhD, a biomedical scientist and science writer currently working in the field of microbiology and immunology.
The much-contested question of whether or not a gene can be patented is under judicial scrutiny once again. The U.S. Supreme Court listened to oral arguments today regarding Myriad Genetic’s patent of two genes, BRCA1 and BRCA2, which have been linked to increased cancer risk in both women and men. The American Civil Liberties Union is challenging this patent on behalf of a group of researchers, medical groups and patients. The timing of the hearing is rather serendipitous, just one day after the 10th anniversary of the completion of the Human Genome Project.
This guest post comes from Edward Grandi, Executive Director of the American Sleep Apnea Association.
The public health community is on alert over a new strain of avian flu that has made the jump from birds to people, resulting in six confirmed deaths in China.
’At this point it’s a matter of anxious waiting and good surveillance,’ Research!America Board member Georges Benjamin, MD, executive director of the American Public Health Association, told Politico Pro.
Next Monday, April 8, is the Rally for Medical Research! Speakers at the rally will include Research!America Chair the Honorable John Edward Porter, Rep.
Scientists at Memorial Sloan-Kettering Cancer Center, a Research!America member, have successfully treated a handful of leukemia patients with cutting-edge immune cell therapy. This therapy, similar to previous trials at the University of Pennsylvania and the National Cancer Institute, modifies the patient’s immune cells so that they recognize and kill the cancer cells.